<SEC-DOCUMENT>0001628908-25-000064.txt : 20250508
<SEC-HEADER>0001628908-25-000064.hdr.sgml : 20250508
<ACCEPTANCE-DATETIME>20250508161258
ACCESSION NUMBER:		0001628908-25-000064
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250508
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250508
DATE AS OF CHANGE:		20250508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolent Health, Inc.
		CENTRAL INDEX KEY:			0001628908
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		ORGANIZATION NAME:           	07 Trade & Services
		EIN:				320454912
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37415
		FILM NUMBER:		25926240

	BUSINESS ADDRESS:	
		STREET 1:		1812 NORTH MOORE ST, SUITE 1705
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22209
		BUSINESS PHONE:		571-389-6000

	MAIL ADDRESS:	
		STREET 1:		1812 NORTH MOORE ST, SUITE 1705
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22209
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>evh-20250508.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:4dad6eb2-4338-4c03-89c6-abd39549b077,g:d4527ce2-6b32-49d2-bdc4-4e60a4b34290,d:0c08e97a22d6419eafc97e5307637e17-->
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>evh-20250508</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001628908</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="evh-20250508.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-08</xbrli:startDate><xbrli:endDate>2025-05-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0c08e97a22d6419eafc97e5307637e17_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">UNITED STATES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WASHINGTON, D.C. 20549</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to Section 13 or 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May 8, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported)  &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Evolent Health, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:365.25pt"><tr><td style="width:1.0pt"/><td style="width:109.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:6.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:7.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:7.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:7.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37415</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">32-0454912</ix:nonNumeric></span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Commission File Number:&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1812 N. Moore Street</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 1705</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Arlington</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Virginia</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">22209</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Address of principal executive offices)(zip code)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">571</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">389-6000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric>  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric>  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric>  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric>  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"/><td style="width:232.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:85.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:186.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">EVH</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i0c08e97a22d6419eafc97e5307637e17_7"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  &#160;&#160;&#160;&#160;Results of Operations and Financial Condition</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;8, 2025, Evolent Health, Inc. (the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">") issued a press release announcing its financial results for the quarter ended March&#160;31, 2025, a copy of which is furnished herewith as Exhibit 99.1.  </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i0c08e97a22d6419eafc97e5307637e17_10"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 9.01.  &#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.833%"><tr><td style="width:1.0%"/><td style="width:14.879%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.487%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a2025q1exhibit991.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a2025q1exhibit991.htm">Press Release of Evolent Health, Inc. dated May 8, 2025.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.</span></td></tr></table></div><div id="i0c08e97a22d6419eafc97e5307637e17_13"></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;     </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;             </span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:231.00pt"><tr><td style="width:1.0pt"/><td style="width:82.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:144.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Jonathan D. Weinberg</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jonathan D. Weinberg</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General Counsel and Secretary</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:  May&#160;8, 2025 </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a2025q1exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i2c566f7e331b4621a8695c787f49e186_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><img alt="evhnewlogo.jpg" src="evhnewlogo.jpg" style="height:133px;margin-bottom:5pt;vertical-align:text-bottom;width:288px"></div><div style="text-align:center"><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Announces First Quarter 2025 Results</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WASHINGTON (May&#160;8, 2025) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8211; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evolent Health, Inc. (NYSE&#58; EVH) (&#8220;Evolent&#8221; or the &#8220;Company&#8221;), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March&#160;31, 2025. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, &#8220;Evolent Health kicked off 2025 with first quarter results at the high end of our expectations, and we are reiterating our outlook for full year 2025 revenue and Adjusted EBITDA. We continue to see a very strong selling environment and we achieved significant organic growth with five new revenue agreements announced today. Operationally, we continue scaling our innovative oncology condition management solution to help Evolent further impact specialty care member experience, costs and outcomes. Performance Suite margins, including leading indicators on utilization, and AI-based automation initiatives, like Auth Intel, are both currently tracking favorably. From an innovation perspective we remain focused on improving member and provider experience in specialty care, while continuing to manage affordability for the system &#8211; a combination we believe Evolent is uniquely positioned to deliver. In the time ahead we&#8217;ll remain disciplined in capital allocation, prioritizing cash generation and debt paydown. I am proud of our recent progress and I believe that our strong pipeline, low market penetration, innovative product stack and highly engaged team of 4,500 professionals, positions Evolent to deliver sustained value to our shareholders, partners and members in the short and long term.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Highlights from the quarter ended March&#160;31, 2025</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">include (in thousands, except for average PMPM fees and revenue per case)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Results&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,649&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639,653&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,250)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,225)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss margin</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,860&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,097&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA Margin</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Lives on Platform&#47;Cases</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance Suite</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,486&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,050&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Technology and Services Suite</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,079&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,302&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Administrative Services</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cases</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Unique Members</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,628&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,888&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average PMPM Fees&#47; Revenue per Case</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance Suite</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.57&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.19&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty Technology and Services Suite</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Administrative Services</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.72&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.57&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cases</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,849&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The rising medical costs impacting health plans continue to drive robust demand for Evolent&#8217;s complex specialty care solutions. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evolent announced the following new revenue agreements as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Two new health plans are rolling out our surgical management solutions to their commercial lines of business&#58; one is a Blues plan located in the South and one is a large national plan rolling out the solutions initially to two of its large southern states.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Expanded the geographic reach of our existing medical oncology Technology &#38; Services solution with one of our national payer clients expected to cover an additional 800,000 Medicare Advantage lives. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">An existing partner in a southern state will be adding our Technology and Services solution for advanced imaging and cardiac imaging for approximately 100,000 lives in their Medicaid line of business.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Expanded our musculoskeletal services to the Medicare Advantage line of business for an existing partner in the northeast, expected to add over 100,000 lives.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">Financial Results of Evolent Health, Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our earnings releases, prepared remarks, conference calls, slide presentations and webcasts, we may use or discuss  financial measures not prepared in accordance with generally accepted accounting principles (&#8220;GAAP&#8221;). Definitions of the non-GAAP financial measures as well as reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are presented herein. See Non-GAAP Financial Measures for more information.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Reported Results </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Evolent Health, Inc. reported the following results in accordance with GAAP (in thousands, except for per share data)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.816%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,649&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639,653&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,178&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535,547&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,409&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,104&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,250)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,225)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss margin </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share attributable to common shareholders of Evolent Health, Inc.&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.63)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Total cash and cash equivalents was $246.5 million as of March&#160;31, 2025. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Adjusted Results </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Evolent Health, Inc. reported the following adjusted results (in thousands, except for per share data)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.538%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted cost of revenue </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,521&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,542&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted selling, general and administrative expenses </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,268&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,014&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,860&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,097&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA margin</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted income (loss) attributable to common shareholders </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,445&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,144&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted income (loss) per common share attributable to common shareholders&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Business Outlook&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not believe it can meaningfully reconcile guidance for non-GAAP Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. because the Company cannot provide guidance for the more significant reconciling items between net income (loss) attributable to common shareholders of Evolent Health, Inc. and Adjusted EBITDA without unreasonable effort. This is due to the fact that future period non-GAAP guidance includes adjustments for items not indicative of our core operations, and as a result from changes to our business due to transactions and other events. Such items may, from time to time, include loss on repayment&#47;extinguishment of debt&#59; gain (loss) from equity method investees, loss on option exercise, change in fair value of contingent consideration, change in tax receivable agreement liability, other income (expense), gain (loss) on disposal of non-strategic assets, right-of-use asset impairments, losses on lease terminations, repositioning costs, stock-based compensation expense, severance costs, dividends and accretion on Series A Preferred Stock and transaction-related costs. Such adjustments may be affected by changes in ongoing assumptions, judgements, as well as nonrecurring, unusual or unanticipated charges, expenses or gains (losses) or other items that may not directly correlate to the underlying performance of our business operations. The exact amount of these adjustments is not currently determinable but may be significant.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Second Quarter 2025 Guidance</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2025, revenue is expected to be in the range of $440.0 million to $470.0 million. Adjusted EBITDA is expected to be in the range of $33.0 million to $40.0 million.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Full Year 2025 Guidance</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reiterated its outlook for the full year ending December 31, 2025, with revenue expected to be in the range of approximately $2.06 billion to $2.11 billion, and adjusted EBITDA expected to be in the range of approximately $135.0 million to $165.0 million.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Additional Outlook Information</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reiterated its expectation to deploy approximately $35 million in cash for capitalized software development during 2025.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This &#34;Business Outlook&#34; section contains forward-looking statements, and actual results may differ materially. Factors that may cause actual results to differ materially from our current expectations in addition to those set forth above are set forth below in &#34;Forward Looking Statements - Cautionary Language&#34; and Evolent Health, Inc.'s filings with the Securities and Exchange Commission (&#34;SEC&#34;). </font></div><div><font><br></font></div><div><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Web and Conference Call Information</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Evolent Health, Inc. will hold a conference call to discuss its financial performance and related matters this evening, May&#160;8, 2025, at 5&#58;00 p.m., Eastern Time. To listen to a live broadcast via the internet and view the accompanying materials, please visit the Company's Investor Relations website at http&#58;&#47;&#47;ir.evolent.com. To participate by telephone, dial (855) 940-9467, or (412) 317-6034 for international callers, and ask to join the &#34;Evolent Health call.&#34; Participants are advised to dial in at least fifteen minutes prior to the call to register. The call will be archived on the Company's website for one week and will be available beginning later this evening. Evolent invites all interested parties to attend the conference call.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Evolent </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Evolent specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolent.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contacts&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:106%">investorrelations&#64;evolent.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Revenue Agreements</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent reports the number of new revenue agreements signed for Performance Suite, Specialty Technology and Services Suite, Administrative Services and Case-based products. A new revenue agreement includes incremental revenue to the Company reflecting contracts for services to both new partner entities, corporations or health plans as well as additional sales to existing partners. New revenue agreements may include incremental services, geographic, or line of business expansions or a combination thereof. The conversion of Specialty Technology and Services Suite contracts to Performance Suite are also included in this definition. The Company does not count renewals for existing scope, growth of membership within an existing contract scope or transaction-related purchase agreements, if applicable, in this metric.  </font></div><div><font><br></font></div><div><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lives on Platform and Per Member Per Month (&#8220;PMPM&#8221;) Fee</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Suite Lives on Platform are calculated by summing monthly members covered for specialty care services for contracts not under ASO arrangements, plus members managed by Complex Care in capitation arrangements and divided by the number of months in the period. Specialty Technology and Services Suite Lives on Platform are calculated by summing monthly members covered for oncology, cardiology, musculoskeletal, advanced imaging and other diagnostic specialty care services for contracts under ASO arrangements divided by the number of months in the period. Administrative Services Lives on Platform are calculated by summing monthly members covered for administrative services implementation and core performance services divided by the number of months in the period. Cases are calculated by summing the number of individuals receiving services through our surgery management and advanced care planning programs in a given period. Members covered for more than one category are counted in each category. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Suite Average PMPM fee is defined as revenue pertaining to our Performance Suite during the period reported divided by Performance Suite Lives on Platform for the period divided by the number of months in the period. Specialty Technology and Services Suite Average PMPM fee is defined as revenue pertaining to the Specialty Technology and Services Suite during the period reported divided by Specialty Technology and Services Suite Lives on Platform for the period divided by the number of months in the period. Administrative Services Average PMPM fee is defined as revenue pertaining to the Administrative Services during the period reported divided by the Administrative Services Lives on Platform for the period divided by the number of months in the period. Revenue per Case is calculated by the revenue pertaining to surgery management and advanced care planning programs divided by the number of cases for a given period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average Unique Members are calculated by summing members covered by our Performance Suite, Specialty Technology and Services Suite and Administrative Services. In cases where partners cross between multiple solutions, we only capture members from the solution with the maximum number of members.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses Lives on Platform, PMPM fees, Cases, Revenue per Case and Average Unique Members because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="i2c566f7e331b4621a8695c787f49e186_4"></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div id="i2c566f7e331b4621a8695c787f49e186_7"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.<br>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> <br>(unaudited, in thousands, except per share data)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5pt"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:492.75pt"><tr><td style="width:1.0pt"></td><td style="width:372.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,649&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639,653&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,178&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535,547&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,409&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,104&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,058&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,503&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on lease termination</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,906&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,908&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485,271&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,062&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,622)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,409)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,385)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,997)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from equity method investees</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on option exercise</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,348)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivables agreement liability</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,148)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,715)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before preferred dividends and accretion of Series A Preferred Stock</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,618)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,280)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends and accretion of Series A Preferred Stock</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,632)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,945)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,250)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,225)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.63)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares outstanding</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,315&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,141&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,250)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,225)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes, related to&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,226)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,276)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i2c566f7e331b4621a8695c787f49e186_10"></div><hr style="page-break-after:always"><div style="min-height:27pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, except share data)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:533.25pt"><tr><td style="width:1.0pt"></td><td style="width:351.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:84.25pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(unaudited)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,547&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,203&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,239&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,295&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,496&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414,681&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,652&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,938&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,934&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607,117&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,059&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,998&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments and equity method investees</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,569&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,588&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,440&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,151&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets - operating</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,726&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,134&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,188&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,569&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,334&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,378&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,881&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,156&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137,320&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137,320&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,653,451&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,544,411&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,813&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,025&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,531&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,361&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability - current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,187&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,717&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,914&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,719&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,017&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,793&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,467&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance - based arrangements</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,842&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,705&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739,097&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715,501&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,532&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490,520&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,269&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivables agreement liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,105&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,105&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - noncurrent</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,585&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,969&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,114&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,900&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524,702&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352,979&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mezzanine Equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred class A common stock - $0.01 par value&#59; 50,000,000 shares authorized&#59; 175,000 issued, respectively</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,228&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,173&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' Equity </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock - $0.01 par value&#59; 750,000,000 shares authorized&#59; 117,397,804 and 116,575,773 shares issued, respectively</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,802,634&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803,786&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,729)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,753)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (accumulated deficit)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(845,435)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780,817)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost&#59; 1,537,582 shares issued, respectively</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,123)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,123)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935,521&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,259&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities, mezzanine equity and shareholders' equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,653,451&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,544,411&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><font><br></font></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="i2c566f7e331b4621a8695c787f49e186_13"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (unaudited, in thousands)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:506.25pt"><tr><td style="width:1.0pt"></td><td style="width:381.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Provided by Operating Activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before preferred dividends and accretion of Series A preferred stock</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,618)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,280)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash and restricted cash provided by (used in) operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,908&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) from equity method investees</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on option exercise</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,348&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,058&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,503&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,081&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,786&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax benefit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on lease termination</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,906&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivables agreement liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use operating assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current operating cash inflows (outflows), net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of acquisitions&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net and contract assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,815)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,009&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current and non-current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,729)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,166&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,193)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,556)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,264&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,421)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,879)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,635&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,820)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,582)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,279)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,510&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,137&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,409)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by operating activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,565&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,909&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Used In Investing Activities</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for asset acquisitions and business combinations</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,498)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,385)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments and contributions to equity method investees</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in internal-use software and purchases of property and equipment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,595)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,347)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in investing activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,093)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,732)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Provided by Financing Activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in working capital balances related to claims processing</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,476)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,520&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,755)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt, net of offering costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(529)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,500)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of preferred dividends</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,577)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,078)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes withheld and paid for vesting of equity awards</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,593)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,334)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,854&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,882&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash and cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,349&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,021&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:506.25pt"><tr><td style="width:1.0pt"></td><td style="width:381.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of beginning-of-period</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,496&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,457&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of end-of-period</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,845&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,478&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><div id="i2c566f7e331b4621a8695c787f49e186_16"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div id="i2c566f7e331b4621a8695c787f49e186_19"></div><div><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company views the following activities as integral to understanding its non-GAAP financial measures&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">Repositioning costs include severance, termination benefits and related payroll taxes of $1.8 million, dedicated employee costs of $1.2 million, third-party professional services of $3.5 million and office space consolidation costs of $3.5 million for the three months ended March 31, 2024. Repositioning costs are not part of Evolent&#8217;s normal course of business and are incurred when there is a business reason to enact a repositioning plan. Adjusting for these costs gives a better view of Evolent&#8217;s normal operating costs. We only adjust costs that (i) are included within selling, general and administrative expenses on the consolidated statement of operations and comprehensive income (loss), (ii) meet the criteria outlined within the respective repositioning plan&#59; and (iii) do not relate to normal business operations or ongoing activities. Our 2023 Repositioning Plan concluded in the second quarter of 2024.</font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.96pt">Dedicated employee costs primarily include project management and technology staff costs needed to migrate acquired businesses to Evolent&#8217;s integrated technology platform and costs related to the consolidation of internal operations, strategies, processes and platforms. Dedicated employee costs are limited to employees that will have no role in ongoing operations and have no planned role at Evolent once the repositioning activities are completed. </font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.96pt">Professional services costs primarily relate to services provided by a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods. </font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.96pt">Office space consolidation costs include early termination penalties and associated expenses.</font></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-13.5pt"><font><br></font></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">Transaction-related costs include but are not limited to integration consultants, investor outreach services, external valuation and accounting advisory services, legal fees, transaction bonuses paid to certain employees and other transaction related costs. We adjust these costs because transaction-related costs are expensed when incurred and are not indicative of Evolent&#8217;s normal operating costs.</font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><font><br></font></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">Purchase accounting adjustments include amortization expense on intangible assets such as corporate trade names, customer, relationships, provider network contracts and existing technology related to acquisitions and business combinations. We believe it is important for the reader to understand that revenue generated from acquisitions is included within revenue in calculating adjusted income to common shareholders however amortization expense from acquired intangible assets is excluded in determining adjusted income to common shareholders because it does not directly relate to the services performed for the Company&#8217;s customers.</font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to disclosing financial results that are determined in accordance with GAAP, we present Adjusted Cost of Revenue, Adjusted Selling, General and Administrative Expenses, Adjusted Income (Loss) Attributable to Common Shareholders, Adjusted Income (Loss) per Common Share Attributable to Common Shareholders, Adjusted EBITDA and Adjusted EBITDA Margin, which are all non-GAAP financial measures, as supplemental measures to help investors evaluate our fundamental operational performance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Cost of Revenue and Adjusted Selling, General and Administrative Expenses are defined as cost of revenue and selling, general and administrative expenses calculated in accordance with GAAP, respectively, adjusted to exclude the impact of stock-based compensation expenses, severance costs, transaction-related costs and repositioning costs. Management believes Adjusted Cost of Revenue and Adjusted Selling, General and Administrative Expenses are useful to investors, because they facilitate an understanding of our long-term operational costs while removing the effect of costs that are not a representative component of the day-to-day operating performance of our business, and are useful to management as supplemental performance measures. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, provision for income taxes, depreciation and amortization expenses, change in the tax receivable agreement liability, gain (loss) from equity method investees, loss on option exercise, change in fair value of contingent consideration, other income (expense), net, loss on lease termination, repositioning costs, stock-</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based compensation expense, severance costs, dividends and accretion of Series A Preferred Stock and transaction-related costs. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management believes that Adjusted EBITDA is useful to investors because it allows investors to evaluate the Company&#8217;s performance using tools that management uses to evaluate past performance and prospects for future performance. Management also uses Adjusted EBITDA as a supplemental performance measure because the removal of adjustments to net loss attributable to common shareholders of Evolent Health, Inc. allows us to focus on operational performance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Adjusted EBITDA Margin is defined Adjusted EBITDA divided by Revenue. Management believes that this measure is useful to investors because it allows further insight into the period over period operational performance. Management also uses Adjusted EBITDA Margin as a supplemental performance measure because it allows the investor to understand operational performance compared to revenues over time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Income Attributable to Common Shareholders is defined as net loss attributable to common shareholders of Evolent Health, Inc. adjusted to exclude gain (loss) from equity method investees, loss on option exercise, other income (expense), net, provision for income taxes, change in fair value of contingent consideration, change in tax receivable agreement liability, purchase accounting adjustments, loss on lease termination, repositioning costs, stock-based compensation expense, severance costs, transaction-related costs and the tax impact of non-GAAP adjustments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Income per Share Attributable to Common Shareholders is defined as Adjusted Income Attributable to Common Shareholders divided by Weighted-Average Common Shares, and reflects the adjustments made in those non-GAAP measures.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management believes that Adjusted Income Attributable to Common Shareholders and Adjusted Income per Share Attributable to Common Shareholders are useful to investors because they provide a measure of the Company&#8217;s net profitability on a more comparable basis to historical periods and provide a more meaningful basis for forecasting future performance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These adjusted measures do not represent and should not be considered as alternatives to GAAP measurements, and our calculations thereof may not be comparable to similarly entitled measures reported by other companies. A reconciliation of these adjusted measures to their most comparable GAAP financial measures is presented in the tables below. We believe these measures are useful across time in evaluating our fundamental core operating performance.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div id="i2c566f7e331b4621a8695c787f49e186_22"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of Adjusted Results of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"></td><td style="width:73.939%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of Adjusted Cost of Revenue to <br>Cost of Revenue</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,178&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535,547&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted cost of revenue</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,521&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,542&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of Adjusted Selling, General and Administrative Expenses to <br>Selling, General and Administrative Expenses</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,409&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,104&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,424&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,781&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction-related costs</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,929&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted selling, general and administrative expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,268&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,014&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div></div></div><div id="i2c566f7e331b4621a8695c787f49e186_25"></div><hr style="page-break-after:always"><div style="min-height:49.5pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of Adjusted EBITDA to Net Income (Loss)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Attributable to Common Shareholders of Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:397.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$(72,250)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$(25,225)</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Net loss margin</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(14.9)%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(3.9)%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,385)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,997)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,470)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(565)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,058)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,503)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from equity method investees</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on option exercise</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,348)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,908)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on lease termination</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,906)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,929)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,081)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,786)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,014)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends and accretion of Series A Preferred Stock</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,632)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,945)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction-related costs</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(703)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,860&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,097&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA margin</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><font><br></font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:49.5pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div id="i2c566f7e331b4621a8695c787f49e186_28"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Reconciliation of Adjusted Income Attributable to Common Shareholders to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Loss Attributable to Common Shareholders</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:385.00pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,250)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,225)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from equity method investees</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on option exercise</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,348)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,470)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(565)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,908)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,365)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,360)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on lease termination</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,906)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,929)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,081)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,786)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,014)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction-related costs</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(703)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax impact </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,418&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted income attributable to common shareholders</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,445&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,144&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per share attributable to common shareholders</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.63)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted income per share attributable to common shareholders</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,315&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,141&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Non-GAAP financial information for the periods shown are adjusted for an assumed provision for income taxes based on our statutory federal tax rate of 21%. Due to the differences in the tax treatment of items excluded from non-GAAP earnings, our estimated tax rate on non-GAAP income may differ from our GAAP tax rate.</font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="i2c566f7e331b4621a8695c787f49e186_31"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS - CAUTIONARY LANGUAGE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Certain statements made in this report and in other written or oral statements made by us or on our behalf are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like&#58; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;aim,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;shall,&#8221; &#8220;may,&#8221; &#8220;might&#8221; and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to our ability to weather current dynamics, continue to expand our footprint, future actions, trends in our businesses, prospective services, new partner additions&#47;expansions, our guidance and business outlook and future performance or financial results, and the closing of pending transactions and the outcome of contingencies, such as legal proceedings. We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements.&#160;Risks and uncertainties that may cause actual results to vary materially, some of which are described within the forward-looking statements, include, among others&#58;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the significant portion of revenue we derive from our largest partners, and the potential loss, termination or renegotiation of our relationship or contract with any significant partner, or multiple partners in the aggregate&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the increasing number of risk-sharing arrangements we enter into with our partners&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the growth and success of our partners and certain revenues from our engagements, which are difficult to predict and are subject to factors outside of our control, including governmental funding reductions and other policy changes&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our ability to accurately predict our exposure under performance-based contracts&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">failure by our customers to provide us with accurate and timely information&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our ability to recover the upfront costs in our partner relationships and develop our partner relationships over time&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our ability to attract new partners and successfully capture new opportunities&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our ability to offer new and innovative products and services and our ability to keep pace with industry standards, technology and our partners&#8217; needs&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our ability to maintain and enhance our reputation and brand recognition&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our dependency on our key personnel, and our ability to attract, hire, integrate and retain key personnel&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">risks related to completed and future acquisitions, investments, alliances and joint ventures, which could divert management resources, result in unanticipated costs or dilute our stockholders&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our ability to effectively manage our growth and maintain an efficient cost structure&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our ability to partner with providers due to exclusivity provisions in our and some of our partner and founder contracts&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">risks related to managing our offshore operations and cost reduction goals&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our ability to estimate the size of our target markets for our services&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">consolidation in the health care industry&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">competition which could limit our ability to maintain or expand market share within our industry&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">risks related to audits by CMS and other governmental payers and actions, including whistleblower claims under the False Claims Act&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">evolution of the healthcare regulatory and political framework&#59;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">restrictions on the manner in which we access personal data and penalties as a result of privacy and data protection laws&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">data loss or corruption due to failures or errors in our systems and service disruptions at our data centers&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">liabilities and reputational risks related to our ability to safeguard the security and privacy of confidential data&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our ability to obtain, maintain and enforce intellectual property rights and protect our trademarks and trade names, including from third parties alleging that we are infringing or violating their intellectual property rights&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our ability to protect the confidentiality of our trade secrets&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">risks associated with our use of artificial intelligence (&#8220;AI&#8221;) and machine learning models&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our use of &#8220;open-source&#8221; software&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our reliance on third parties and licensed technologies&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">restrictions on our ability to use, disclose, de-identify or license data and to integrate third-party technologies&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our reliance on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners and operating our business&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">material weaknesses in the future may impact our ability to conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our ability to achieve profitability in the future&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the impact of additional goodwill and intangible asset impairments on our results of operations&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our obligations to make material payments to certain of our pre-IPO investors for certain tax benefits we may claim in the future&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our obligations to make payments under the tax receivables agreement that may be accelerated or may exceed the tax benefits we realize&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">our ability to utilize benefits under the tax receivables agreement&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the terms of agreements between us and certain of our pre-IPO investors may contain different terms than comparable agreement we may enter into with unaffiliated third parties&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">Our inability to obtain financing may result in a reduction in the ownership of our stockholders&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the conditional conversion features, and changes in accounting treatment, of the 2025 Notes and the 2029 Notes, which, if triggered, may adversely affect our financial condition and operating results&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.8pt">our ability to raise funds necessary to settle conversions of our notes in cash, to repurchase our notes for cash upon a fundamental change or to pay the redemption price for any notes we redeem&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.8pt">interest rate risk and other restrictive covenants under the Credit Agreement and the terms of our Cumulative Series A Convertible Preferred Shares, par value $0.01 per share (&#8220;Series A Preferred Stock&#8221;)&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.8pt">our indebtedness, our ability to service our indebtedness, and our ability to obtain additional financing on favorable terms or at all&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.8pt">our ability to service our debt and pay dividends on our Series A Preferred Stock&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.8pt">interference with our ability to access the revolving credit facility under our Credit Agreement&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.8pt">the potential volatility of our Class A common stock price&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.8pt">our Series A Preferred Stock has rights, preferences and privileges that are not held by and are preferential to the rights of holders of our Class A common stock, and could in the future substantially dilute the ownership interest of holders of our Class A common stock&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.8pt">the potential decline of our Class A common stock price if a substantial number of shares are sold or become available for sale, including those issuable upon conversion of our Series A Preferred Stock&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.8pt">provisions in our certificate of incorporation and by-laws and provisions of Delaware law that discourage or prevent strategic transactions, including a takeover of us&#59;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.8pt">provisions in our certificate of incorporation which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.8pt">our intention not to pay cash dividends on our Class A common stock&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.8pt">the impact of litigation proceedings, government inquiries, reviews, audits or investigations&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.8pt">risks related to the failure of any bank in which we deposit our funds, which could reduce the amount of cash we have available to meet our cash commitments and make additional investments&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.8pt">public health emergencies, epidemics, pandemics or contagious diseases&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.8pt">the cost of compliance with sustainability or other environmental, social responsibility or governance law and regulations&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.8pt">the impact of increasing inflationary pressures and rising consumer costs on our business</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The risks included here are not exhaustive. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Our periodic reports and other documents filed with the SEC include additional factors that could affect our businesses and financial performance. Moreover, we operate in a rapidly changing and competitive environment. New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. In addition, we undertake no obligation to publicly update any forward-looking statements to reflect events or circumstances that occur after the date of this release.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>evh-20250508.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:4dad6eb2-4338-4c03-89c6-abd39549b077,g:d4527ce2-6b32-49d2-bdc4-4e60a4b34290-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:evh="http://www.evolenthealth.com/20250508" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolenthealth.com/20250508">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20250508_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20250508_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20250508_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageCoverPage" roleURI="http://www.evolenthealth.com/role/CoverPageCoverPage">
        <link:definition>0000001 - Document - Cover Page Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>evh-20250508_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:4dad6eb2-4338-4c03-89c6-abd39549b077,g:d4527ce2-6b32-49d2-bdc4-4e60a4b34290-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CoverPageCoverPage" xlink:type="simple" xlink:href="evh-20250508.xsd#CoverPageCoverPage"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CoverPageCoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_318ad4df-2f09-4f41-be47-8e0206204edf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_DocumentInformationTable_318ad4df-2f09-4f41-be47-8e0206204edf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationDocumentAxis_e5e61639-c4a3-4533-b333-73d30f236459" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationDocumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_318ad4df-2f09-4f41-be47-8e0206204edf" xlink:to="loc_dei_DocumentInformationDocumentAxis_e5e61639-c4a3-4533-b333-73d30f236459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentDomain_e5e61639-c4a3-4533-b333-73d30f236459_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_DocumentInformationDocumentAxis_e5e61639-c4a3-4533-b333-73d30f236459" xlink:to="loc_dei_DocumentDomain_e5e61639-c4a3-4533-b333-73d30f236459_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentDomain_b98015e7-3b88-44b0-add9-de94a5e8ed67" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_DocumentInformationDocumentAxis_e5e61639-c4a3-4533-b333-73d30f236459" xlink:to="loc_dei_DocumentDomain_b98015e7-3b88-44b0-add9-de94a5e8ed67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6f3a45f9-462b-45a6-9036-ea4a0adb2f68" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_Security12bTitle_6f3a45f9-462b-45a6-9036-ea4a0adb2f68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_74da0624-13d3-43c6-adab-7c20370b9511" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_74da0624-13d3-43c6-adab-7c20370b9511" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_334fa88d-2044-4662-a2b6-26800bcff89a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_DocumentType_334fa88d-2044-4662-a2b6-26800bcff89a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_498dee89-246a-4b8d-b6b1-6e080a996c68" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityRegistrantName_498dee89-246a-4b8d-b6b1-6e080a996c68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_313ff923-18b8-48e0-97cc-9deac4cb5857" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_CityAreaCode_313ff923-18b8-48e0-97cc-9deac4cb5857" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_56ee382c-817a-4b89-a6f0-9ac93a322d3b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_LocalPhoneNumber_56ee382c-817a-4b89-a6f0-9ac93a322d3b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_73a7cc16-da7d-4fce-a769-1c59d29223a7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityFileNumber_73a7cc16-da7d-4fce-a769-1c59d29223a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_24a56e31-2065-4c39-be6c-b56086df8e27" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityTaxIdentificationNumber_24a56e31-2065-4c39-be6c-b56086df8e27" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e1805b42-9d59-4651-a65e-01edc6499c03" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityAddressAddressLine1_e1805b42-9d59-4651-a65e-01edc6499c03" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_661d3136-8f12-4ad4-bf90-9eaafa1f94c3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityAddressAddressLine2_661d3136-8f12-4ad4-bf90-9eaafa1f94c3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4a6c690b-ebd6-4d2c-adab-e62b5c58a182" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityAddressCityOrTown_4a6c690b-ebd6-4d2c-adab-e62b5c58a182" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_25d85365-8e39-4168-ab3a-40966c1c3fc0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityAddressStateOrProvince_25d85365-8e39-4168-ab3a-40966c1c3fc0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e4a1e024-d251-4875-ab26-1029a8fd0ce4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityAddressPostalZipCode_e4a1e024-d251-4875-ab26-1029a8fd0ce4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_fe239610-1cbb-409b-9b72-538b01fb861d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_WrittenCommunications_fe239610-1cbb-409b-9b72-538b01fb861d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_06a56f4b-bcf7-4ffe-96fb-f0fee09b03b6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_SolicitingMaterial_06a56f4b-bcf7-4ffe-96fb-f0fee09b03b6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_86c16f63-79c7-4f3f-b56e-674cab5c9497" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_PreCommencementTenderOffer_86c16f63-79c7-4f3f-b56e-674cab5c9497" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_a86ab24e-b45d-45d8-ad78-ecb1d8167892" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_a86ab24e-b45d-45d8-ad78-ecb1d8167892" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_786c4e88-21a8-434c-9aea-adb5bf1b5b1d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityEmergingGrowthCompany_786c4e88-21a8-434c-9aea-adb5bf1b5b1d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7e74e687-f560-4b7a-979b-63aeae00eddd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_TradingSymbol_7e74e687-f560-4b7a-979b-63aeae00eddd" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_110f97f7-5990-43f8-a788-f30148fbc2e4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_SecurityExchangeName_110f97f7-5990-43f8-a788-f30148fbc2e4" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7ea9860a-dd72-4646-b1b2-da2df19d718b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_DocumentPeriodEndDate_7ea9860a-dd72-4646-b1b2-da2df19d718b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0515db6c-bab0-4a14-8872-89512cfe6607" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityCentralIndexKey_0515db6c-bab0-4a14-8872-89512cfe6607" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_442b0ea9-07c1-43d5-b6ba-67d921c27b50" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_AmendmentFlag_442b0ea9-07c1-43d5-b6ba-67d921c27b50" xlink:type="arc" order="22"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>evh-20250508_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:4dad6eb2-4338-4c03-89c6-abd39549b077,g:d4527ce2-6b32-49d2-bdc4-4e60a4b34290-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b0b9c1b6-ba99-48c8-84f7-a67d6ffabf2d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationDocumentAxis_57211b16-d34c-478c-9a1b-e353be0f556e_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationDocumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information, Document [Axis]</link:label>
    <link:label id="lab_dei_DocumentInformationDocumentAxis_label_en-US" xlink:label="lab_dei_DocumentInformationDocumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information, Document [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationDocumentAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationDocumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationDocumentAxis" xlink:to="lab_dei_DocumentInformationDocumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6c80a9ea-298c-4ddd-b155-606c67c727fa_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentDomain_8ef03236-18ab-465e-869c-7306cbf07fff_terseLabel_en-US" xlink:label="lab_dei_DocumentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document [Domain]</link:label>
    <link:label id="lab_dei_DocumentDomain_label_en-US" xlink:label="lab_dei_DocumentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentDomain" xlink:to="lab_dei_DocumentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b1a369cf-2573-4cfb-ab80-becb93e2b814_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_d25584a8-470b-45be-875a-81ac8d3c5595_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_18964d71-d6b6-4576-a234-d9117b63c5de_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4f834c57-9175-4e36-a5a4-340a4b6b1de4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d77f9328-134b-42b2-94a8-f49ee405034d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_866383ae-7400-4016-bcae-314a9eddf298_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b66f20f8-a852-4e79-a5ac-c12329f57b8a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4d089275-2ea4-42b4-a866-d625719c79bc_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_6ea1d6fe-8dc2-4a3d-b93c-916e9eeb7813_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_56176165-1fa5-4826-8542-d770b0867a5d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2f64a448-6888-48b0-a00a-fe12491ac244_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_db7c31e0-f339-4639-8ba1-0461903189a9_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_88e19cf4-e626-4fb8-8755-871c6819c8a9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_fdfbbb6e-c2f3-492e-9168-5e01be3410f1_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2e3f9037-3431-48b8-b6b1-b7579afcd78c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_2a9f1e54-680f-4b2b-9ed8-d9dd3c9729f9_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_19dfe693-3856-4737-ad31-2312042a8c66_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3b488e6e-edc8-471f-bf1e-18bc1ce00b57_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_0383efc7-b1c5-4bb6-8bb0-8fbfd83d1c94_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_701b08e1-3256-418a-86f6-4cdf861dd4fc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_aec82d01-b7ac-418a-93d5-4495d6c89677_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5ae07218-b743-4ce7-a754-7713b2429377_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2f6fd92a-7630-419a-8fd2-c7e9668fd8ea_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7d70375b-fa14-4fe6-9627-5ddc3bf0ebd0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>evh-20250508_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:4dad6eb2-4338-4c03-89c6-abd39549b077,g:d4527ce2-6b32-49d2-bdc4-4e60a4b34290-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CoverPageCoverPage" xlink:type="simple" xlink:href="evh-20250508.xsd#CoverPageCoverPage"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CoverPageCoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_907c72fc-6f89-4dc6-99a7-6bc23e3c3414" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_318ad4df-2f09-4f41-be47-8e0206204edf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_907c72fc-6f89-4dc6-99a7-6bc23e3c3414" xlink:to="loc_dei_DocumentInformationTable_318ad4df-2f09-4f41-be47-8e0206204edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationDocumentAxis_e5e61639-c4a3-4533-b333-73d30f236459" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationDocumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_318ad4df-2f09-4f41-be47-8e0206204edf" xlink:to="loc_dei_DocumentInformationDocumentAxis_e5e61639-c4a3-4533-b333-73d30f236459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentDomain_b98015e7-3b88-44b0-add9-de94a5e8ed67" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationDocumentAxis_e5e61639-c4a3-4533-b333-73d30f236459" xlink:to="loc_dei_DocumentDomain_b98015e7-3b88-44b0-add9-de94a5e8ed67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_318ad4df-2f09-4f41-be47-8e0206204edf" xlink:to="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6f3a45f9-462b-45a6-9036-ea4a0adb2f68" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_Security12bTitle_6f3a45f9-462b-45a6-9036-ea4a0adb2f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_74da0624-13d3-43c6-adab-7c20370b9511" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_74da0624-13d3-43c6-adab-7c20370b9511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_334fa88d-2044-4662-a2b6-26800bcff89a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_DocumentType_334fa88d-2044-4662-a2b6-26800bcff89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_498dee89-246a-4b8d-b6b1-6e080a996c68" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityRegistrantName_498dee89-246a-4b8d-b6b1-6e080a996c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_313ff923-18b8-48e0-97cc-9deac4cb5857" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_CityAreaCode_313ff923-18b8-48e0-97cc-9deac4cb5857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_56ee382c-817a-4b89-a6f0-9ac93a322d3b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_LocalPhoneNumber_56ee382c-817a-4b89-a6f0-9ac93a322d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_73a7cc16-da7d-4fce-a769-1c59d29223a7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityFileNumber_73a7cc16-da7d-4fce-a769-1c59d29223a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_24a56e31-2065-4c39-be6c-b56086df8e27" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityTaxIdentificationNumber_24a56e31-2065-4c39-be6c-b56086df8e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e1805b42-9d59-4651-a65e-01edc6499c03" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityAddressAddressLine1_e1805b42-9d59-4651-a65e-01edc6499c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_661d3136-8f12-4ad4-bf90-9eaafa1f94c3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityAddressAddressLine2_661d3136-8f12-4ad4-bf90-9eaafa1f94c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4a6c690b-ebd6-4d2c-adab-e62b5c58a182" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityAddressCityOrTown_4a6c690b-ebd6-4d2c-adab-e62b5c58a182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_25d85365-8e39-4168-ab3a-40966c1c3fc0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityAddressStateOrProvince_25d85365-8e39-4168-ab3a-40966c1c3fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e4a1e024-d251-4875-ab26-1029a8fd0ce4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityAddressPostalZipCode_e4a1e024-d251-4875-ab26-1029a8fd0ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_fe239610-1cbb-409b-9b72-538b01fb861d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_WrittenCommunications_fe239610-1cbb-409b-9b72-538b01fb861d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_06a56f4b-bcf7-4ffe-96fb-f0fee09b03b6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_SolicitingMaterial_06a56f4b-bcf7-4ffe-96fb-f0fee09b03b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_86c16f63-79c7-4f3f-b56e-674cab5c9497" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_PreCommencementTenderOffer_86c16f63-79c7-4f3f-b56e-674cab5c9497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_a86ab24e-b45d-45d8-ad78-ecb1d8167892" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_a86ab24e-b45d-45d8-ad78-ecb1d8167892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_786c4e88-21a8-434c-9aea-adb5bf1b5b1d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityEmergingGrowthCompany_786c4e88-21a8-434c-9aea-adb5bf1b5b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7e74e687-f560-4b7a-979b-63aeae00eddd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_TradingSymbol_7e74e687-f560-4b7a-979b-63aeae00eddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_110f97f7-5990-43f8-a788-f30148fbc2e4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_SecurityExchangeName_110f97f7-5990-43f8-a788-f30148fbc2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7ea9860a-dd72-4646-b1b2-da2df19d718b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_DocumentPeriodEndDate_7ea9860a-dd72-4646-b1b2-da2df19d718b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0515db6c-bab0-4a14-8872-89512cfe6607" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_EntityCentralIndexKey_0515db6c-bab0-4a14-8872-89512cfe6607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_442b0ea9-07c1-43d5-b6ba-67d921c27b50" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_050887b8-fcf7-40d3-8834-613c52f0669d" xlink:to="loc_dei_AmendmentFlag_442b0ea9-07c1-43d5-b6ba-67d921c27b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>evhnewlogo.jpg
<TEXT>
begin 644 evhnewlogo.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %R R # 2(  A$! Q$!_\0
M'@ !  $$ P$!              D!!P@* @4&! /_Q !>$  ! P,"! (%! L+
M"@$)"0 !  (#! 4&!Q$($B$Q"4$3%")183)Q@;,5%C<X0E5UD92QT1<9(U)7
M=(*5H;+2&"0S0U-68G)VP<(E)S0V.6-SDK0F-41%5(.%H^'_Q  < 0$  @,!
M 0$              P0! @4&!PC_Q  T$0$  @(! @0$!0,$ @,      0(#
M$002,043(4$&%#)1(C-A8G%"@9$'4J&Q%<'1X?#_V@ , P$  A$#$0 _ )4T
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$5-UT.89UC^
M!6B:YY#=Z:U440YG2U$@;T^ [GZ%F(FTZK&Y(]>SOT5FZ3B]TAK:J*GBSB@=
M+*X,:'-D:"2=AU+=@KN45=3W"F944L\=3!(-V2Q.#FN'O!'0J2^+)B_,K,?S
M#::S'>'T(BINHFJJ+IK_ )A9,7A=)=[M1VYK6\_^<S-8=O> 3N?H7P8WJ=BF
M6["SY#;Z]Q=R!D=0WG)]P:3N5O&.\UZHK.FNX>H14W"JM&PB(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@IOW3F5I^)?7.GT#TWJ,A?2&NKI9!2T4'9CIG D%Q\F@ GX[;*,
M3).+S5C)+G)639E7TH,OI64]&X111'W-;[OG76X?AF;F5F]9U#H\;@Y.3'5$
MZA,F#NJJ/_@RXU[Y>LLI<)SRLDNQN,A;0W:8@21R'<\DAZ M/D>X/3S6?S7;
M_!5>5Q<G#R>7D5\_'OQ[]%WPWZ\TV/V:MN=9(R*EI(G32/D<&@!H)[GLH<]:
M]8+UK)G-PO=TJII*=TKA1TKW[LIHMSRL:!T[=SYE2P:ZXM59II#EMCH7MCJZ
MVWR1QN?VWVW_ .RACGA?3S/BD:6O82US2-B"%Z?X=QXYC)DGZHTGXM8]9GNX
M;D>:RRX"M=[IC.H%-A-PJIJJQWC>.GBDD]FEF )#AOV! (('F0L3?)7,X:L5
MJ<PUMQ*WTLKX'^O,F=*T$\C6;O.^W;Y.WTKTW.QX\O&O6_;4K62*VI.TQH/1
M6@XF==F:(8,:RF;%47RM<8**"1P'*=CO(1W+6]/I(5WP>@*P6\2 S_9O#PYH
M]7%//R. Z[\S=_\ LOG7A7'IR>73'?M_\//Y;36DS#$K*<PO&:W>>YWNX3W*
MLE<2Z2H>7;;DG8 ]AN>P774-=46VICJ:2:2FJ(G!T<L3BUS"/,$=05^"+ZY%
M*UCIB/1R=RD'X*^)2NU!@DP[)IVS7:BA$E'6R/'/4Q@[%CA^$]O0[^8WW66
M*BUX,>8<0N,<H&_-+ON?+T3]U*0.@7R_QSC4XW*UCC46C?\ VZF"TVIZJ[KB
M9F@D%P!]Q*Q4XF^*N;%*^HQ7$)PVYQ$LK+@!OZ!W\1F_X0\SY=EA]=<WR"]W
M">NKKS6U%5,[F?(Z=VY/YU;X'P[GY>*,N2W1$]O>?_3A\OQO%Q[SCI7JF/\
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MNLW8_D_%<'QCB8^+GB,7I$QO7V?4?].O'N9XYX;?YV>J^.VNK[QK?K^L>_\
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M;KT(ZA1$^">!^ZGJ2?/["T_UZEW'14<M/*O-4E9W&Q$10MA$1 1$0$1$!$1
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M)"+;4T<=U:UW21TS7"/I\.4J-197>%U<JFBXR<.A@G?%%515<<[&G82-$#W
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M3IIT_=G''KM<9<3V^E<EQ/;Z5QEAK;\2?W?M0_RY5?6.5MO(JY/$G]W[4/\
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M"N'JJH<ER"5N7YQ .9E7*S:DI'^^&,CJ1Y.=U'DLRP-ER\_)ZOP4[)JUUZR
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M&JI8:RGE@GB;-#*TL?'(.9KVD$$$'N""IL66<-MPTM6):N2#HIB>)CPC\3U
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M^&1PSXO3:40ZBWJV4%XOEWG>:.:HC]*:2&-W*  [HUY<"21Y$+M>-' YM,>
MBV8E/5MKIK-%1T3ZEC.42%O0D#R6+G"'QB9#PI88:+(L.K[QAU[E]=M]8Q[H
MRP@ADA8X[M<SV?DC8[H:]&6/B-\-&'9'HK?<]IK=3VG)<?8*OUNCB:PU<9<&
MNCEV^5W!![C96+TBXA\GH?#CSMM/(UM98*MMDIZQ[R]Y@J".;OV+0\@;=ALO
M-<27&WDG%_;:+3?3W$*^DI:^K F:U_IIZT@^PS9HV8WN2#[A[EEYI7P245FX
M0:[2Z]FG;>KY"ZKKJR-IV96'VHB>OM>C(:/CRH=H]6#7!=Q(:7\/UHK;CD.
MW;),PGJB8[M3Q1RM@A ]EL?.=VNW+MR._1=_Q@<4NEG$AA<C;=IY?;1F<,L<
ME-=Y::)O,T=',E<WVG-Y2=A[]E\&D.L>6<!^47W"-1,#9D%D=)Z>..:G8US'
MD[">*5S2',<!V/N\E=?)?$LLE_JZ&W:>Z/4UQKY:F%I];IHWF1I<.:-K&-WY
MCV!)VZHR^)O$%DTGAD53XY*B&YTM>W&*BKJ]W22T[R22TGJ#RD-!\ME[WPO.
M'O#:S28ZAW.UT]XO]97RPPOKH&R"C;$[8>CW[$[[DK)+6_0VAX@N'RMQ<6UN
M,U=PIXZ^FIC&UGJM8&\S1(&CKL3RE1\Z \4V=<"=?>=/-0,3K*ZS13>EAI21
M$^F>X^U)&\C9['@;[(Q'9(;JIP?Z4ZPW.CN.1XM3.K:>7TIGHO\ -WSG;;:4
MLZO;T[%6%\5&UTEDX8+%;Z&!E+1TU[IHH88QLUC1'*  %;*_>)?G^JV8V2SZ
M.X-*9?3D20UC34FK&W8ANW(!U).ZN;XI3ZRLX7<>DK8!!7/O-(Z>%AY@QYAD
MY@#[@=T(]%PO#^J:2BX.,2J*Z6*"BBAJGSRSN#6-8)7\Q<3T VW5D+3QN<.F
MB-]J;)@. 5MYY>9K[O;*.,OJ27.<[=[SSN )/4]/<O4Z$XA>,Y\,_P"P5B?-
M'=:JV5C88XF;OF(E>?1 ?\8'+]*QMX'^)73/ARMM_L.I6(34=ZDJ3(+J;?Z>
M8@>SZ%S'#=H:0>H[[HQ"V7&;K%A&LN866^X?A=?A=4V)[:X55,R#UJ0NYFR>
MQW<.VZD]UY>Z3@;R1SW%SG8>PEQ.Y)] SJHW.-_7FBXA[W:+KBV(55EQ.TF2
MCAN$M*(O7)'>T"0 -O9'0=5)%KJ">!O(@ 2?M/CZ;?\ N&(RQU\'?_U-U)_G
MU)]6]6CU<_\ :H6__J.V_4L5WO!Z8Z/#M20X$?Y]2=QM_JWJT>K<3SXIMO<&
MN+?MCMO4 _[)B'O*6"K@I2QTU3'"61@DR3-&S0.I))[!1@<56JMYXR-9K?HS
MI2^.;':>?_/*R%H;!42L)YYGN'>*/KM[SU'DKB>)WQ2UN*6\Z48VZJI;E<(&
MU%UK8P6@4SM^6)CAW+MCN1V V\U8G@_XJ]+.%[&IWNQ2[WG+K@-J^Z !K6L!
M]F*('LT=S[RA"2GAQX?K#PYZ;46+64FHE'\+6U[V[/JIS\IY]P\@/(*.CAQ_
M]IY>ORQ=_P"Z]9S\+W&)8N)ZOOM+9[)76EUICBD>:P@AX>2!MM\RP:X<HGM\
M3F\N+7!IO-WZ['^*]"/=<KQA8S-0:9L;\IU15@?/LQ9-\*O#;A&GVB>-P#&K
M9/=*ZW1RW&LF@;-)4/D:"\%SAOR^YO8+&GQ>6.?!I?RM)VJ:H] 3Y,6=VDW3
M3+%OR;!_<"'LBIXY\,MW#;Q9XWD.$P06Y\\=->(J&*!K*>GE9*6;-:.G*>3<
M_$E7>\6K4&ZMP[3G'&O8VVW5K[I4M#?:=+&UH9U]W\([I\R\#XL<;G\0>'<K
M7$"RQ=@3_P#B7K,3B]X8G\26AMLH[2V"/*[7%%4VV:<AH?[ #XB[\$.'7YP$
M'W<&G#9A.E^C>+U]':J6OO=TH(JZJNM73L=.\RM#^0';HUN^P'P6-WBD\.&&
M8YA5OU&LE%!9+SZ]'05--1Q-CBK!)S'G<T?A-Y>X[@]5:S3+BIUUX.;=%@N6
M8=4W&UT[I#2172&3TL;=]N6*4;@Q[]0#[^G1>+XJ,NUSUUPVEU"SVR.QO"Z&
M2&GM]%RF"*5\W,1(QCCS2$AO5QZ#8=MT9CNS_P##*^])QO\ G=;]>Y94'Y)6
M+?AH4TM-PE8R)8W1EU36/;SC;=IF=L1\"LI#V*-41W'-_P"T%L?_ ,6R_P!]
MJR_\3[KPGW?\IT?UA6(?'+$]WB"61P:X@2V7J ?X[5E]XGC2[A1NP +C]DZ+
ML-_]849^RWGA?:&X76:(,S2X8_17'(JRXS,%;61"5T4<9V8(^8>QW.^W=6\\
M5[1G$L/MN'Y;8[136BZ5U7+157J438F3-#2\/<!W=OY^Y9!^%\TLX4[2' @B
MX5?0C;\,*VGC ,<_33 0UI)^R\W8$_ZE".[*'A%R:XYCPVZ>WF[5!JKC56J,
MS3$;%Q!+0?S *[I[*Q_! "WA2TT!Z$6IO0_\[E? C<$(PB'X Z^FM?'1>F5D
M\=(^?[*P1-G<&%\AEZ,&_=QV.P4O*C2XZ.$3+\/U,_=LTP;45,WK#*VMI*.(
M&:AG8/\ 31M ZL('7S!W/FOQPSQ=ZZSV*GH\RP!]=>X]Q-54-4*=D@_!/HW@
MD'W]=D929'L5%9XGN;7/-.(3%--7U#Z2RTT=*[^#<2'R5+^4R.;V):.R[&X>
M(-K'K[J/C-KTAQ22U0Q3-FFH7#UDUFQ]L32; -B (WVV(]ZN1XAO"[E6I5FL
M6J&,VUC,LLU(P76WT1+YWM:>8/C=^%Z,@]/,'X(1Z,JM)N&_ ]),%@Q>T6"A
MFIQ3B"KJ:BF8^6M.WM.E)'7<[]/+LHW..[2NW\./$GB>4X0QF/TUQ?'6MIK:
M\QNAG9)M(6 =&-<"  .G=7&TW\6?[7<-H[9F^&5E=D-'3"-]933B)M6YO1KG
M-<-V$C;<]1ONK:6NS9YXAW$O0Y2ZPS6#$K>^%LE0\.,5+31NY@WF=T?*[?R'
M7Z$(W"^7BM71E]T#TZN+6.C95W1LP8_Y30ZF<=C^=>]\.WAWPFT\/^-9?/9J
M.ZW^]L?5RUM;3,DDA',6>C82.C=F_P!J\CXN5/R:.X/%$S9K+T6AK6] ! [W
M*_7 2TMX2--P001;W="/_>O0]F!_BH:9XUIMJ=B5TQ>U0V.LNM%-451H1Z-C
MI(Y &O#1T#NO4CNLZM7JB6JX'+_//(Z::3"N=\CSNY[C3-))/O*P_P#&&B=)
MFNGG*TNVMM7V!_VK5E[JNTG@7O0 ._VD#IMU_P#16HPPS\*;17#]0JG-L@R6
MR4M[JK6ZFIJ2.NC$L4?.'.<_D/3FW:-CY=5?3Q-=&<,9P^U^6P8_1T>06RKI
MF4];21")_*^0,<UW*/:;L>@/8KPW@[QN9CNI0<TM_P ZHNXV_P!6]7N\31I?
MPE9&&@DFLHNPW_UP1GW6^X"\^K+%P*Y%>:^JK*QMFFN#*8,?S/AC:QO(R/W
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<"(B B(@(B("(B B(@(B("(B B(@(B("(B#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Cover Page<br></strong></div></th>
<th class="th"><div>May 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Evolent Health, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">389-6000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0454912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1812 N. Moore Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Arlington<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EVH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  08,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001628908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( )R!J%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( )R!J%I]L,\=[P   "L"   1
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
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M4$L! A0#%     @ G(&H6GVPSQWO    *P(  !$              ( !PP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ G(&H6IE<G",0!@  G"<
M !,              ( !X0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " "<@:A:\$)2R70$  !<$0  &               @($B"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ G(&H6I^@&_"Q @  X@P
M  T              ( !S P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "<
M@:A:EXJ[',     3 @  "P              @ &H#P  7W)E;',O+G)E;'-0
M2P$"% ,4    " "<@:A:Y6B*[#D!   R @  #P              @ &1$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ G(&H6B0>FZ*M    ^ $  !H
M             ( !]Q$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ G(&H6F60>9(9 0  SP,  !,              ( !W!(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  )A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="evh-20250508.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CoverPageCoverPage</Role>
      <ShortName>Cover Page Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="evh-20250508.htm">evh-20250508.htm</File>
    <File>evh-20250508.xsd</File>
    <File>evh-20250508_def.xml</File>
    <File>evh-20250508_lab.xml</File>
    <File>evh-20250508_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "evh-20250508.htm": {
   "nsprefix": "evh",
   "nsuri": "http://www.evolenthealth.com/20250508",
   "dts": {
    "inline": {
     "local": [
      "evh-20250508.htm"
     ]
    },
    "schema": {
     "local": [
      "evh-20250508.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "evh-20250508_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "evh-20250508_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "evh-20250508_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 28,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.evolenthealth.com/role/CoverPageCoverPage",
     "longName": "0000001 - Document - Cover Page Cover Page",
     "shortName": "Cover Page Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:Security12bTitle",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "evh-20250508.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:Security12bTitle",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "evh-20250508.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document [Domain]",
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information, Document [Axis]",
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628908-25-000064-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628908-25-000064-xbrl.zip
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M=YW?M^ &48< *8?:)YC0$;Z)CP)-_8!ZQ37QX'3*XV]P)<4J(K;B $%N)7=
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M\(U^9'%=DQ"A_M"FL*BF=(;FU%D@EI;E=$QQ>RU)<]&SVHZM$9C40+#4$K&
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M<CTFW/1AR&2<* A%D*GPEE!T1:PM"DII)W/J,S0#5 PU_DDBP"<+(%.%MP;
M!2*$'1D)/B$<(B(^%26X,/.&&#RFXN#O@SB/9(<1\B<[9OAEKVY(17$12E]:
MJG@[=Y@(RL/ZYLQ08R]V'TV2V N$F"TB*#&B&R//84VA>UX<J,5%$N"Y!58<
M@[IZEY^!4GY]#RQU1D)U4)5,8I\I5R,Q9-OE(E($4G0 D15=RFVQ_$Q1$@_3
M!VKV4?8P]P!* ADR$"TKGPA]7( 6,62QB/4PH3O[-MZ6U HL#DN<AP.[ ']C
MEU*Q#&>H_A6!YJ8<O#$/(1 $O42"S@P%#[>.WJ&!%;%40#5:[ );9  4$OZ2
M^3:E53;*RI>ED_+QDA1[8P]18?+AKHM\39PORD.ZE)&Q$)E7.D!9.HUHF&&G
MS) ?$L-SI%_E:<_B>)J,)<%S9JH*ZM):!]@H3ZH*O"\W"9"5H#5U*$!&MY8/
M<8J#2'B.5A[#+@(6!,4?Y-<&&(N>)[J6(8 L#WJ6+F\5##UON'SRW/#'/L\0
MB&./2)5AD.8W%AC&$&#W1[/4\AL6IZR!Y4=Q[./A>!4SFU(PLG'-@$V!LAQ>
M";@\JJ6T='X^%*V[(DC!4&OGRR4>A"J-12+W6+^RXBPN[MP59X;SDUIY, ]G
ME^\^?U+A>N@N1669/X0Y@P8L8L- 'KX3QW_%$76S^@Y/SX*,\VU5D=2)>2RX
M1]4%$&;$V5*FD('<U AQ\>$!>"ZNLF^8=Z!HHTQDSH T?QNB[E6G96F DSR?
M^ UH:BBR<R6'1\J%<BHF.0&2I ^,17@,KGRT=:W +"?-R5.^I:IE6(61B):F
M7&#+^?I4TG3Y.#-@T.$06$/N@I0M&T/]G5+_D[ <'NUEY/ >G9E GGG$.2T%
M5"KE!R8FF(TBT<#0Q)SO?['"(BN */P.5IY,V<BH.D@@EJL\U2U(YGEQ%LF-
MGSSGHI4'R#A-QR4?XY3-D_; I;Z\I,XD6"2 AWDP&L&:]BW!$=3'[PJK4)B1
M,KU181,6?5SR)B@<K#%7;)(X5!>NL!N]54=F:9 P<?0?['R&<1R8D0;WCEF:
MAJS$,T42@T@P .;7H@F06YR[G68<F"AAI0<$)H8G2#9%RHIO4!46)QD.<96(
MLY^I]#L^F\C A"G'2 .9<'2FVGN03[")X8==\H/P!&$N&>&HP=VN4BQCX4.^
M1TZX9WB"J R[KC$]04JN"@V=BX4"(R _7&>33$:^D5OH.-#RBEP+ODJ%(?R9
M,P  T!2Y%440+%3?Y)Z&&2/_:#::=JF\6KZK5C14>ADU2;[79IADUT(#9V(
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M9M\<_ ]02P$"% ,4    " "<@:A:D.S#W-U;  ",>04 %0
M@ $     83(P,C5Q,65X:&EB:70Y.3$N:'1M4$L! A0#%     @ G(&H6IAJ
M5HT2$   2W0  !               ( !$%P  &5V:"TR,#(U,#4P."YH=&U0
M2P$"% ,4    " "<@:A:HS, 2GH"   L"   $               @ %0;
M979H+3(P,C4P-3 X+GAS9%!+ 0(4 Q0    ( )R!J%IZ->S<Y <  '8Z   4
M              "  ?AN  !E=F@M,C R-3 U,#A?9&5F+GAM;%!+ 0(4 Q0
M   ( )R!J%J9:4Z"S@L  #YG   4              "  0YW  !E=F@M,C R
M-3 U,#A?;&%B+GAM;%!+ 0(4 Q0    ( )R!J%IJ3370HP<   0]   4
M          "  0Z#  !E=F@M,C R-3 U,#A?<')E+GAM;%!+!08     !@ &
+ (4!  #CB@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>evh-20250508_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="evh-20250508.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2025-05-08</startDate>
            <endDate>2025-05-08</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001628908</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-05-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Evolent Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37415</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">32-0454912</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1812 N. Moore Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 1705</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Arlington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">22209</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">571</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">389-6000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">EVH</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
